Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Chemotherapy for Advanced Pancreatic Cancer

Objective: To investigate the safety and efficacy of anti-PD-1 antibodies in combination with chemotherapy in the treatment of advanced pancreatic cancer. Methods: The clinical data of 18 patients with advanced pancreatic cancer who received anti-PD-1 antibody combined with chemotherapy were retrospectively analyzed. Safety, objective response rate, disease control rate, progression-free survival and overall survival were analyzed. Results: One patient achieved a complete response, nine patients had a partial response, five patients had stable disease and three patients had progressive disease. Progression-free survival and overall survival were shown to be significantly prolonged in both PD-L1-positive and high microsatellite instability (MSI-H) patients. Conclusion: Anti-PD-1 antibodies in combination with chemotherapy are safe and effective in the treatment of advanced pancreatic cancer.In recent years, encouraging results have been achieved with a new treatment for advanced cancer, immunotherapy. Immune checkpoint inhibitors are now being used as a more established form of immunotherapy. During immunotherapy, immune checkpoint inhibitors effectively dismantle the ‘camouflage’ of tumor cells, allowing immune cells to regain the ability to recognize and remember them, allowing the body's immune cells or drugs to kill tumor cells with precision. This study analyzed 18 patients with advanced pancreatic cancer, in whom immunotherapy in combination with chemotherapy achieved better results than conventional treatment with minimal side effects, making immunotherapy one of the most promising treatments for tumors.